Diagnostic significance of leptin in patients with ischemic heart disease on the basis of metabolic syndrome

Abstract

Summary. This article presents changes in leptin, carbohydrate and lipid metabolism in patients with coronary heart disease and complicated by metabolic syndrome (MS). Obesity is positively correlated with loss of health and reduced life expectancy, as it contributes to a high risk of many pathological processes, such as coronary heart disease, stroke, liver cirrhosis, type 2 diabetes and a number of different cancers. Obesity and insulin resistance are major components of the metabolic syndrome and major risk factors for cardiovascular disease. High leptin levels are positively associated with systemic markers of inflammation.

The aim of the study – to research the levels of leptin, glucose, triacylglycerols (TG), glycated hemoglobin (HbA1c) in the blood of patients with coronary heart disease and patients with coronary heart disease on the background of metabolic syndrome.

Materials аnd Methods. 120 patients with verified coronary heart disease were examined, including 60 patients with coronary heart disease without MS (30 men, 30 women) and 60 patients with coronary heart disease on the background of MS (29 men, 31 women). The mean age of patients was (50±5) years. Control group – 30 healthy people of appropriate age and sex.

Results. Studies have shown that obesity is accompanied by high levels of leptin, which deepens insulin resistance and is a trigger for coronary heart disease. Also, more pronounced changes in carbohydrate and lipid metabolism in patients with coronary heart disease on the background of metabolic syndrome, which indicates the severity of the clinical course of coronary heart disease on the background of MS.

Conclusions. Studies have shown that leptin resistance can be a potential cause of insulin resistance and therefore obesity, which ultimately leads to metabolic syndrome and the development of coronary heart disease. The data indicate a greater tendency to obesity in women with coronary heart disease complicated by MS.